Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
115 hedge funds and large institutions have $1.24B invested in Spark Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 51 increasing their positions, 20 reducing their positions, and 20 closing their positions.
349% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $3.65M
155% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 20
117% more capital invested
Capital invested by funds: $570M → $1.24B (+$670M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 20
10% more funds holding
Funds holding: 105 → 115 (+10)
Top Buyers
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$32.2M |
| 2 |
JP Morgan Chase
New York
|
+$28.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$21.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.5M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$17.2M |
Top Sellers
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$6.13M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$5.85M |
| 3 |
Morgan Stanley
New York
|
-$4.61M |
| 4 |
Axa
Paris,
France
|
-$4.59M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.51M |
ONCE Hedge Fund Activity: Q2 2016 in Review
115 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q2 2016, worth a combined $1.24B — up 117% from $570M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ONCE positions and 20 closed out — a net gain of 10 holders — while 51 added to existing stakes and 20 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $32.2M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $6.13M sold.
- 115 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q2 2016, up from 105 in Q1 2016.
- Funds reported $1.24B of Spark Therapeutics, Inc. Common Stock stock for Q2 2016, up 117% quarter-over-quarter.
- 30 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q2 2016 and 20 closed out, a net change of +10 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q2 2016 was Lord, Abbett & Co, an estimated $32.2M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q2 2016 was Waddell & Reed Financial, an estimated $6.13M sold.
Based on aggregated 13F filings for Q2 2016.